-
Mashup Score: 1
BIIB059, a monoclonal antibody that binds blood dendritic cell antigen 2 and inhibits interferon 1, improves total active joint count at 24 weeks in patients with systemic lupus erythematosus, findings from the LILAC trial show.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
#ACR20 news: Richard Furie (@NorthwellHealth) presents #LILAC trial findings showing #BIIB059, an antibody that blocks blood dendritic cell antigen 2, improves total active joint count in patients with #SystemicLupusErythematosus https://t.co/fbqJwl6bPF